RFA-DA-26-034: Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on the Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic Opioids

RFA-DA-26-034: Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on the Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic Opioids

Executive summary

RFA-DA-26-034 is a NIH NOFO led by the Chemical Countermeasures Research Program (CCRP). The opportunity supports research on ultra-potent synthetic (UPS) opioids, including fentanyl, carfentanil, nitazenes, and combinations like fentanyl with xylazine. It is designed for investigators who can study acute exposure mechanisms, delayed toxic effects, and mitigation strategies.

The call is for R01-style grant support (clinical trials are not allowed) and is aimed at trans-NIH priorities across NIDA, NIAID, and NHLBI partners. The program has recurring annual due dates in both 2026 and 2027 and an expiration window through November 2027.

If you are building a proposal around acute overdose biology, respiratory compromise pathways, neurocircuit effects, or downstream persistent injury caused by UPS exposure, this opportunity is unusually focused and potentially a strong fit.

Key details

What this opportunity funds

This NOFO is not a broad drug program; it has a narrow problem focus:

• acute effects of UPS opioids and combinations,
• delayed or persistent pathophysiology after acute exposure,
• mechanistic research that can produce actionable evidence for treatment or mitigation.

The intent is to support work that can move from fundamental mechanism to practical response readiness, including molecular, cellular, genetic, neural, developmental, and systems-level approaches. The opportunity explicitly prioritizes studies that can clarify why severe outcomes happen, which pathways are central, and how interventions might interrupt downstream injury.

The program is anchored in public-health threat context, with UPS opioids framed as high-consequence chemicals. This framing matters because review expectations will reward projects that can frame relevance to prevention, emergency care context, or emergency response readiness instead of purely descriptive science.

What kinds of topics are commonly appropriate

Examples include:

• molecular and cellular mechanisms of ultra-rapid toxic injury from UPS opioids,
• translational models to parse respiratory, neurological, and cardiovascular sequelae,
• studies identifying biomarkers or injury signatures that persist after apparent recovery,
• validation and target discovery for post-exposure reversal/mitigation candidates,
• pathways and timing of delayed morbidity in survivors,
• pregnancy and developmental consequences where appropriate.

Topics that are explicitly out of scope

NIH states several examples of non-responsive proposals. In practice, these are high-risk rejection triggers:

• projects not centered on DHS-designated CoC opioids,
• behavioral treatment-focused SUD programs rather than mechanistic UPS toxicity or delayed effects,
• efficacy-only work on known MCMs without causal mechanistic depth,
• prophylactic administration designs or co-administration paradigms that do not match the acute-exposure framing,
• chronic/sub-chronic models that do not emulate acute exposure and acute-to-delayed injury progression.

You should treat this as a hard filter when building your specific aims page.

Who is likely to be a strong fit

A strong fit applicant usually has all of these elements:

1. Existing expertise in neuroscience, pharmacology, toxicology, cardiopulmonary injury, infectious/immune responses, or related pathophysiology.
2. A mechanistic question that can separate acute toxic phase effects from delayed injury.
3. Clear plans for reproducibility, with multiple assay systems where possible.
4. A translational path that avoids early-stage hype and instead demonstrates how findings could guide mitigation design.
5. Institutional readiness to handle NIH systems and submission compliance.

The opportunity is open to a broad set of U.S. applicant types: higher education, nonprofits, small businesses, for-profit entities, local/federal government entities, and selected public organizations. It is not a non-U.S. only program, and foreign organizations are not eligible as primary applicants.

Why this can be a strategic fit even if you are not primarily opioid-focused

If your lab studies overdose, respiratory depression, signal pathways, toxicology, or emergency pharmacology but not opioid addiction directly, your project can still fit if it addresses acute UPS mechanisms and delayed outcomes with strong translational framing. This is different from treatment-centered behavioral work.

Eligibility rules you should verify early

Before drafting the science section, verify the minimum compliance conditions in writing:

• You must apply as an eligible U.S. organization.
• You need full registrations in SAM, eRA Commons, and Grants.gov in advance.
• Use official NIH application pathways only: ASSIST, institutional S2S to Grants.gov/eRA Commons, or Grants.gov Workspace with eRA Commons tracking.
• Clinical trials are explicitly prohibited.
• Application types are limited to new and resubmission.

Eligible applicant organizations in NIH terms

The NOFO includes:

• public and private higher-ed institutions,
• nonprofits,
• small businesses and for-profits,
• local and federal governmental organizations,
• selected community and regional entities,
• U.S. territories/possessions.

Commonly missed eligibility prerequisite

A frequent reason for delayed submission is incomplete registration, especially when teams underestimate lead time. NIH clearly notes registrations can take six weeks or more.

Also: an application can be scientifically excellent and still be administratively delayed or rejected if required IDs, profiles, and registrant records are incomplete or inconsistent across systems.

Timeline and cycle map (2026/2027)

This opportunity is unusual because of its recurring cycles and multi-year relevance. Use this practical calendar:

• Open date (earliest submission): October 18, 2025.
• November 18, 2025: cycle due for 2026 review and early 2027 start windows.
• November 18, 2026: new annual target for FY2027 cycle.
• November 18, 2027: final documented cycle within current NOFO window.
• Program expiration: November 19, 2027.

For a planner in 2026, your priority is the 2026/2027 active windows. The opportunity supports ongoing planning for the FY2027 cycle because review and award timelines can span into 2027.

Submission timing to reduce operational risk

All NIH deadlines are local time, 5:00 p.m. applicant organization time. Build a buffer policy:

• Target internal draft-ready package at least 10 business days before official deadline.
• Run a pre-submission systems check at least one week before due date to catch validation errors.
• If changes are required after submission, NIH only accepts corrected submissions before deadline.

Weekend and federal holiday deadline extensions apply in NIH systems rules, but this is a convenience adjustment, not a planning strategy.

Budget and what to expect from NIH funding

The NOFO provides an explicit, modest-budget framework:

• FY2026 total target: up to $2M in aggregate,
• maximum direct costs: $300,000 per year,
• up to 5-year project period depending on scope and feasibility.

This makes the opportunity suitable for focused mechanism projects or coordinated consortium-linked pilot-to-proof stages, but not for large, long-duration, infrastructure-heavy programs.

Budget design implications

Given the cap:

• Focus the budget on critical assays and translation-relevant outputs, not broad exploratory spending.
• Make sure personnel plans align with scope and deliverables.
• Avoid unrealistic duration or staffing assumptions that imply indirect costs and sub-awards not matched to direct activity.
• Include explicit milestones, because review often discounts vague five-year plans without feasibility staging.

Application process and required materials

Your application is only accepted through NIH-compliant electronic systems and cannot be submitted as paper.

Required process channels

Choose one of the submission routes:

1. NIH ASSIST
2. Institutional system-to-system solution with Grants.gov + eRA Commons
3. Grants.gov Workspace + eRA Commons

Core preparation elements

The NOFO’s Section IV and IV-related instructions place specific expectations on your package:

• Follow How to Apply instructions everywhere unless this NOFO says otherwise.
• Ensure Senior/Key Person profile includes valid eRA Commons IDs for PI and PD/PI fields.
• Include a rigorously justified Data Management and Sharing Plan.
• Use required forms and page limits exactly.
• Include clear plans on mechanistic hypotheses, not only descriptive outcomes.

Suggested content sequence

A practical internal sequence to keep your package compliant:

• Aim page: define UPS CoC chemical scope and why your model emulates acute exposure.
• Specific Aims: separate acute and delayed outcome branches if the study includes both phases.
• Approach: include controls and timing windows, and avoid conflating chronic exposure with acute injury frameworks.
• Innovation section: explain what mechanism-level gain is novel, not only technology novelty.
• Expected outcome: map direct outputs to actionable mitigation targets.

Mandatory systems prep checklist

• SAM registration complete
• eRA Commons registration complete
• Common administrative accounts matched to the same organization identifiers
• Grants.gov submission profile complete
• Internal sponsor and signing official aware of deadlines and compliance rules

Review criteria and reviewer priorities

Review follows NIH peer review procedures and focuses on three core factors (importance, rigor and feasibility, investigator/expertise and resources).

How to write to these criteria

For Importance, avoid broad motivation paragraphs. Start with the precise injury gap and explain exactly what is not known about UPS acute and delayed pathophysiology.

For Rigor and Feasibility, provide power/reproducibility rationale where applicable, justify model choice and endpoint timing, and make data integrity plans explicit.

For Expertise and Resources, show why your team can run acute exposure studies and mechanistic follow-up, including cross-domain support for model validation and analysis.

What reviewers penalize

• A proposal that does not clearly stay within acute-exposure scope,
• over-ambitious aims with no mechanistic sequencing,
• weak controls and weak rationale for model selection,
• incomplete systems compliance.

This NOFO includes a top-tier compliance + science gate: if non-responsive, reviews do not happen.

Common mistakes and how to prevent them

1. Treating it as a clinical treatment study

   • Clinical trials are not allowed; avoid any methods section that implies trial operations.

2. Missing the DHS CoC scope

   • The NOFO expects central focus on DHS-listed ultra-potent opioids and relevant combinations.

3. Submitting chronic models only

   • Acute exposure framing is core. Delayed outcomes are allowed only when linked to acute initial injury mechanisms.

4. Inadequate registration lead time

   • Incomplete systems setup creates last-minute failures even after scientific review readiness.

5. Ignoring reviewer-readable flow

   • Applicants who bury mechanism hypotheses in dense prose lose clarity and often lose review confidence.

6. Ignoring review criteria alignment

   • Include explicit text mapped to NIH criteria and avoid generic filler about impact without measurable deliverables.

Practical fit strategy for 2026 and 2027 applicants

If you are preparing for the November 2026 cycle, align your work to the schedule:

• T-14 weeks: finalize collaborators and finalize CoC-focused model strategy.
• T-10 weeks: lock key aims and mechanistic endpoints; start registration status audit.
• T-6 weeks: draft Research Plan, budget, and impact statement.
• T-3 weeks: internal compliance and formatting check for all pages/forms.
• T-1 week: final portal pre-validation in ASSIST or Grants.gov workspace.

If you already missed 2026 and target 2027:

• treat it as a redesign opportunity rather than a rerun,
• incorporate reviewer feedback from any internal pilot submission,
• re-check partner roles for milestone feasibility,
• preserve the same institutional compliance chain.

Official links and next actions

Useful official references:

• NIH NOFO page: https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-034.html
• NIDA funding details and any trans-NIH notices relevant to this NOFO
• NIH grants policy and application instructions

A practical next step is to read the NOFO once with your PI team and convert each required section into a line-item action list. The difference between an unfunded and competitive application is usually not one idea, but one clean system pass plus one clean mechanistic narrative.